Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HEC placebo gel is a hydroxyethylcellulose-based vaginal gel used as an inert control in clinical trials for topical microbicides, such as Starpharma's VivaGel (SPL7013). Unlike the Carbopol-based vehicle placebo, HEC gel is often used as a universal placebo because it lacks significant buffering capacity or intrinsic antimicrobial activity, providing a neutral comparator for assessing the safety, tolerability, and acceptability of active formulations in the prevention of HIV and other sexually transmitted infections. In Starpharma's Phase 1 trials, it was administered intravaginally to healthy, sexually active women to establish a baseline for vaginal health markers and user acceptability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HEC placebo gel.